Dr. Jinyu Zhang | Hepatocellular Carcinoma | Best Researcher Award

Posted on by Pencis

Dr. Jinyu Zhang | Hepatocellular Carcinoma | Best Researcher Award

Fujian Medical University | China

AUTHOR PROFILE

Scopus

JINYU ZHANG: ACADEMIC JOURNEY AND PROFESSIONAL IMPACT

🎓EARLY ACADEMIC PURSUITS

Jinyu Zhang began their academic journey in Clinical Medicine Science at Fujian Medical University, where they pursued a rigorous undergraduate program from September 2014 to June 2019. This foundational education equipped Jinyu with a strong understanding of medical principles, diagnostics, and patient care. Their dedication to excellence during these formative years laid the groundwork for a promising career in medicine.

💼ADVANCED EDUCATION AND SPECIALIZATION

Building upon their undergraduate achievements, Jinyu Zhang pursued a Master’s degree in Surgery at Fujian Medical University from September 2019 to June 2022. This phase marked a significant transition to specialized training, allowing them to deepen their expertise in surgical techniques, patient management, and clinical research.

Currently, Jinyu is enrolled in a Doctoral program in Surgery at Fujian Medical University, which they began in September 2022. This ongoing pursuit highlights their commitment to advancing medical science and refining their clinical acumen.

🔬PROFESSIONAL ENDEAVORS

Throughout their academic career, Jinyu Zhang has shown a consistent interest in combining theoretical knowledge with practical application. Their professional endeavors include:

  • Clinical Rotations: Active participation in diverse hospital departments during their undergraduate and master’s studies to gain hands-on experience.
  • Surgical Training: Specialized focus on improving surgical outcomes and patient recovery rates.
  • Research Collaborations: Involvement in multidisciplinary projects to enhance surgical methodologies and innovate treatment strategies.

🌍CONTRIBUTIONS AND RESEARCH FOCUS ON HEPATOCELLULAR CARCINOMA

Jinyu Zhang’s research primarily focuses on:

  • Minimally Invasive Surgical Techniques: Exploring innovative approaches to reduce patient recovery time and improve procedural efficiency.
  • Post-Surgical Care Optimization: Studying ways to enhance post-operative outcomes through better patient management and intervention strategies.
  • Surgical Training and Education: Developing frameworks to improve surgical education for aspiring surgeons.

Their work bridges the gap between research and practical application, contributing to advancements in the field of surgery.

📚IMPACT AND INFLUENCE

Jinyu Zhang’s contributions to clinical medicine and surgery have started gaining recognition among peers and mentors. Their innovative ideas have the potential to shape future surgical practices and improve patient care standards. Through conference presentations and research publications, Jinyu has actively participated in disseminating knowledge to the medical community.

🔮ACADEMIC CITATIONS

Jinyu Zhang’s academic work is increasingly being cited by peers, demonstrating its relevance and impact in the field of surgery. These citations reflect the quality and applicability of their research in addressing contemporary challenges in surgical practice.

🏆LEGACY AND FUTURE CONTRIBUTIONS

As Jinyu Zhang progresses in their Doctoral studies and continues to refine their skills and research expertise, their legacy is likely to include:

  • Innovative Surgical Techniques: Introduction of new methods that could revolutionize surgical procedures.
  • Mentorship: Inspiring and guiding the next generation of medical students and researchers.
  • Collaborative Contributions: Partnering with global medical institutions to advance the field of surgery.

🌟CONCLUSION

Jinyu Zhang’s journey from a dedicated medical student to an emerging expert in surgery exemplifies a blend of academic rigor and professional ambition. Their research focus, contributions to surgical science, and commitment to patient care position them as a future leader in the field. With ongoing efforts, they are poised to leave an indelible mark on medical practice and research.

 

📊🔬NOTABLE PUBLICATION:
    1. Prognostic value and predication model of microvascular invasion in patients with intrahepatic cholangiocarcinoma: a multicenter study from China
      • Authors: Chen, Y.; Liu, H.; Zhang, J.; …; Zeng, Y.; Liu, J.
      • Journal: BMC Cancer
      • Year: 2021
    1. Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study
      • Authors: Wu, Y.; Liu, H.; Zeng, J.; …; Zeng, Y.; Liu, J.
      • Journal: World Journal of Surgical Oncology
      • Year: 2022
    1. Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients
      • Authors: Lin, K.-Y.; Lin, Z.-W.; Chen, Q.-J.; …; Yang, T.; Zeng, Y.-Y.
      • Journal: Hepatology International
      • Year: 2023
    1. Antiviral Therapy Improves Survival in Hepatocellular Carcinoma with Microvascular Invasion: A Propensity Score Analysis
      • Authors: Kong, J.; Liang, X.; Zhang, J.; …; Liu, J.; Zeng, J.
      • Journal: Digestive Diseases and Sciences
      • Year: 2022
    1. Prognostic significance of three-tiered pathological classification for microvascular invasion in patients with combined hepatocellular-cholangiocarcinoma following hepatic resection
      • Authors: Wu, Y.; Liu, H.; Chen, Y.; …; Zeng, Y.; Liu, J.
      • Journal: Cancer Medicine
      • Year: 2023

Prof. Huaiqing Lv | Neck Tumors | Best Researcher Award

Posted on by Pencis

Prof. Huaiqing Lv | Neck Tumors | Best Researcher Award

Shandong Second Medical University | China

Author Profile

Scopus

🌟 Dr. Lv Huaiqing, M.D.

Chief Physician & Master’s Degree Supervisor

Director of Otorhinolaryngology & Head and Neck Surgery

Linyi People’s Hospital, Shandong Province

👩‍⚕️ Professional Summary:

Dr. Lv Huaiqing is a distinguished Chief Physician and subject leader at Linyi People’s Hospital, specializing in Otorhinolaryngology and Head and Neck Surgery. With extensive experience in clinical practice and research, Dr. Lv has significantly contributed to the field through her leadership roles and numerous scientific projects.

**🌐 Part-Time Roles:

  • Vice Chairman, Otorhinolaryngology, Head and Neck Surgery Committee, Shandong Provincial Medical Association
  • Vice Chairman, Hearing and Balance Medical Association, Shandong Provincial Medical Association
  • Member, Voice Committee, Otorhinolaryngology Committee, Chinese Association of Integrative Medicine
  • Standing Member, Head and Neck Tumor Committee, China Medical Education Association
  • Vice Chairman, Ear, Nose and Throat Committee, Shandong Association of Integrative Medicine
  • Vice Chairman, Pharyngeal, Head and Neck Surgery Committee, Shandong Provincial Association of Health Management
  • Director, Linyi Otorhinolaryngology Quality Control Center
  • Linyi Health Leader
  • Director, Otolaryngology Branch, Linyi Physicians Association

📚 Research Contributions:

Dr. Lv has authored 13 papers as the first author or corresponding author in the past year. She has presided over 3 provincial and municipal level projects, including:

  • Application of Posterior Auricular Groove Incision in Surgery of Benign Tumor of Parotid Gland
  • Evaluation of Orbital Invasion of Sinus Tumor Based on CT, MRI, and Machine Learning Models
  • Posterior Auricular Groove Incision in Surgery of Benign Tumor of Superficial Parotid Gland

Her research has received significant funding of 400,000 RMB and has led to several municipal science and technology awards. The research team excels in various methods, including bioinformatics, meta-analysis, and machine learning predictive models.

🎓 Teaching Commitment:

Currently, Dr. Lv supervises Master’s degree students at Qingdao University, Shandong Second Medical University, and Binzhou Medical College, having guided 10 students to date.

🔬 Current Publications:

She is also the first author or corresponding author of approximately 20 newly accepted and submitted articles in Chinese core or SCI journals.

Dr. Lv Huaiqing’s dedication to otorhinolaryngology, combined with her commitment to research and education, makes her a leading figure in her field.

🔔 Conclusion

Dr. Lv Huaiqing stands out as a prominent leader in Otorhinolaryngology and Head and Neck Surgery, with a rich background in clinical practice, research, and education. Her extensive involvement in various medical associations and committees demonstrates her commitment to advancing the field and enhancing patient care. Through her innovative research projects and dedication to mentoring future healthcare professionals, Dr. Lv continues to make significant contributions to medical science and the development of her specialty in Shandong Province and beyond.

📊🔬NOTABLE PUBLICATION:

    • Circ_0058124 upregulates MAPK1 expression to promote proliferation, metastasis and metabolic abilities in thyroid cancer through sponging miR-940
      • Authors: Sun, D., Chen, L., Lv, H., Liu, X., Zhang, X.
      • Journal: OncoTargets and Therapy
      • Year: 2020

     

    • Predicting biomarkers in laryngeal squamous cell carcinoma based on the cytokine-cytokine receptor interaction pathway
      • Authors: Chen, Q., Wang, D., Chen, Z., Li, P., Lv, H.
      • Journal: Heliyon
      • Year: 2024

     

    • Genetically predicted allergic rhinitis causally increases the risk of erectile dysfunction
      • Authors: Li, P., Meng, Z., Lin, L., Chen, Z., Lv, H.
      • Journal: Frontiers in Genetics
      • Year: 2024

     

    • A novel frameshift mutation of the endoglin (ENG) gene causes hereditary hemorrhagic telangiectasia in a Chinese family
      • Authors: Li, P., Gao, C., Wei, Y., Shao, Q., Lv, H.
      • Journal: European Archives of Oto-Rhino-Laryngology
      • Year: 2024

     

    • Upregulation of microRNA-141 suppresses epithelial-mesenchymal transition and lymph node metastasis in laryngeal cancer through HOXC6-dependent TGF-β signaling pathway
      • Authors: Chen, L., Sun, D.-Z., Fu, Y.-G., Gao, Y., Zhang, X.-Y.
      • Journal: Cellular Signalling
      • Year: 2020

Dr Jianjun Xu | Hepatobiliary Oncology and Cancer | Best Researcher Award

Posted on by Pencis

Dr Jianjun Xu | Hepatobiliary Oncology and Cancer | Best Researcher Award

Union Hospital, Tongii Medical | China

Author Profile

Scopus

Orcid id

🏥 Dr. Jianjun Xu: Pioneering Hepatobiliary Oncology Specialist

👨‍⚕️ Full Name: Jianjun Xu

🏅 Designation: Attending Doctor

🏨 Department:

  • Department of Hepatobiliary Surgery
  • Center for Liver Transplantation

🎓 Qualification: Doctor

🔬 Area of Specialization: Hepatobiliary Oncology and Cancer

💡 Sub Division: Oncology Therapeutics and Novel Approaches

🕒 Total Experience:

  • Work for 2 years
  • Doctor for 3 years
  • Master for 3 years
  • Bachelor for 5 years

 

🎓 Education

📚 2011-2016: Bachelor of Clinical Medicine, School of Medicine, Nanchang University.

🎓 2016-2019: Master of Surgery, Tongji Medical College, Huazhong University of Science and Technology.

🏫 2019-2022: Doctor of Surgery, Tongji Medical College, Huazhong University of Science and Technology.

🏥 Experience

🩺 July 2022 to Present: Attending Doctor at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan 430022, China.

🔬 Contributions to Research, Innovations, and Extension Activities On Hepatobiliary Oncology and Cancer

Throughout his tenure, Dr. Jianjun Xu has made significant contributions to Tumor Research & Development, Innovations, and Extension Activities. Actively participating in research projects, he has advanced the understanding of tumor biology, therapeutic interventions, and patient care outcomes. Leveraging his expertise in hepatobiliary malignancies, Dr. Xu collaborates with interdisciplinary teams to identify novel biomarkers, therapeutic targets, and treatment modalities, aiming to improve patient outcomes and quality of life.

Dr. Xu has also been involved in innovative initiatives to translate research findings into clinical practice. By fostering partnerships with industry stakeholders, academic institutions, and healthcare providers, he has facilitated the development and implementation of cutting-edge technologies and treatment approaches in oncology.

In addition to his research endeavors, Dr. Xu actively engages in extension activities to disseminate knowledge and promote awareness of cancer prevention, early detection, and treatment options within the community. Through educational workshops, public seminars, and outreach programs, he empowers patients, caregivers, and healthcare professionals with the necessary information and resources to combat cancer effectively. His dedication to advancing cancer research, innovation, and community outreach underscores his commitment to making a meaningful impact in the fight against cancer.

NOTABLE PUBLICATION:

Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma

Citation: 52        Year: 2021

High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma

Citation: 18        Year: 2022

Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy

Citation: 09        Year: 2021

Laparoscopic resection of hepatic epithelioid hemangioendothelioma: report of eleven rare cases and literature review

Citation: 05        Year: 2020

Light-triggered polymeric prodrug and nano-assembly for chemo-photodynamic therapy and potentiate immune checkpoint blockade immunotherapy for hepatocellular carcinoma

Citation: 02        Year: 2023